Servier shrugs off a multimillion-dollar investment, abandoning a failed MS drug developed by GeNeuro
Four years after Servier paid $44 million in cash for the option to partner with Geneva-based GeNeuro, the French biotech is shrugging off the investment …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
